5-MeO-EiPT

Last updated
5-MeO-EiPT
5-MeO-EiPT structure.png
Clinical data
Other names5-Methoxy-N-ethyl-N-isopropyltryptamine
Drug class Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • N-ethyl-5-methoxy-N-(1-methylethyl)-1H-indole-3-ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H24N2O
Molar mass 260.381 g·mol−1
3D model (JSmol)
  • CC(C)N(CC)CCC1=CNC2=CC=C(OC)C=C21
  • InChI=1S/C16H24N2O/c1-5-18(12(2)3)9-8-13-11-17-16-7-6-14(19-4)10-15(13)16/h6-7,10-12,17H,5,8-9H2,1-4H3
  • Key:VVEQXDHSGNBFLZ-UHFFFAOYSA-N

5-MeO-EiPT, also known as 5-methoxy-N-ethyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family that has been sold online as a designer drug. [1] [2] [3]

Contents

Interactions

Pharmacology

Pharmacodynamics

5-MeO-EiPT acts as a potent full agonist of the serotonin 5-HT2A receptor. [3] It also shows high affinity for the serotonin 5-HT1A receptor and interacts very weakly with the serotonin transporter (SERT). [3] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. [3] However, it produces a rather weak head-twitch response, suggesting that it might have reduced hallucinogenic effects relative to other psychedelic tryptamines or might be non-hallucinogenic. [3] The serotonin 5-HT1A receptor antagonist WAY-100635 augmented the head-twitch response induced by 5-MeO-EiPT in rodents. [3] The drug also produces hypothermia and hypolocomotion in rodents. [3]

Society and culture

5-MeO-EiPT is illegal in Japan. [4] 5-MeO-EiPT is illegal in Italy. [5] Sweden's public health agency suggested classifying 5-MeO-EiPT as a hazardous substance, on May 15, 2019. [6]

See also

References

  1. ↑ "5-MeO-EiPT". Cayman Chemical. Retrieved 21 July 2015.
  2. ↑ Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry". Forensic Toxicology. 32 (1): 154–161. doi:10.1007/s11419-013-0208-3. S2CID   25134125.
  3. 1 2 3 4 5 6 7 Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, Islam MN, Holy M, Niello M, Pubill D, Camarasa J, Escubedo E, Sitte HH, López-Arnau R (August 2024). "Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties". Mol Psychiatry. 29 (8): 2346–2358. doi:10.1038/s41380-024-02506-8. PMC   11412900 . PMID   38486047.
  4. ↑ "指定薬物名称・構造式一覧（平成27年9月16日現在）" (PDF) (in Japanese). 厚生労働省. 16 September 2015. Retrieved 8 October 2015.
  5. ↑ "Tabella 1 Sostanze Stupefacenti" (PDF) (in Italian). Governo Italiano. March 2017. Archived from the original (PDF) on 6 February 2016. Retrieved 27 March 2017.
  6. ↑ "Folkhälsomyndigheten föreslår att 20 ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 15 May 2019. Archived from the original on 20 October 2021. Retrieved 11 November 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.